Krystal Biotech launches VYJUVEK in Japan at NHI price of 2.955M yen per unit

Krystal Biotech, Inc.

Subsidiary Krystal Biotech Japan KK commenced commercial launch of VYJUVEK (beremagene geperpavec) on Oct 22, 2025.
VYJUVEK added to Japan's National Health Insurance Drug Price List at 2,955,232.7 yen per unit.
Drug indicated for dystrophic epidermolysis bullosa, a rare genetic skin disorder.
Launch follows NHI listing, enabling patient access with government reimbursement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.